Arrowhead Research ARWR Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by Arrowhead Research in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapitalCommonStock.
The official record: Arrowhead Research’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arrowhead Research's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arrowhead Research's additional paid-in capital?
- Arrowhead Research (ARWR) reported additional paid-in capital of $2.4B in Q1 2026.
- How has Arrowhead Research's additional paid-in capital changed year-over-year?
- Arrowhead Research's additional paid-in capital increased by 13.7% year-over-year, from $2.11B to $2.4B.
- What is the long-term trend for Arrowhead Research's additional paid-in capital?
- Over 5 years (2020 to 2025), Arrowhead Research's additional paid-in capital has grown at a 17.3% compound annual growth rate (CAGR), from $965.41M to $2.14B.
- What does additional paid-in capital mean?
- The total amount of money shareholders have paid for company stock above its nominal par value.
- How do you interpret additional paid-in capital?
- An increase indicates successful equity financing rounds, while a decrease is rare and usually relates to specific accounting adjustments.
- How does additional paid-in capital compare across companies?
- Biotech peers often show high levels of APIC due to frequent secondary offerings to fund long-term drug development pipelines.